AMGN (amgen.com) Wutah bathi EPS kuartalan

Can Amgen Inc. (AMGN) maintain its margins amid a fierce battle over patents? Quarterly earnings per share growth provides the answer: the 19.20 level reflects the current value of this metric. The company's own plants in the US and Puerto Rico ensure business stability. The high profitability of complex drugs is offset by massive expenditures on clinical trials for new product lines.

Amgen (AMGN) - Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan saka 04.07.2022 nganti 14.11.2026

Rincian metrik lan analitis perusahaan Amgen Inc. (AMGN)

- nilai pasar lan prakiraan target analis:

Bagan rega Amgen Corporation|AMGN - Bagan rega target

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Amgen Corp|AMGN - Nilai Bisnis

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham Amgen|AMGN - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku amgen.com|AMGN - Total Aset Bisnis

- informasi babagan utang lan solvabilitas:

- indikator bathi lan kelipatan valuasi:

AMGN - Penghasilan resik perusahaan|Bathi sing dikarepake Amgen Inc.|AMGN - Pangali rega marang bathi|Prakiraan rega marang bathi Amgen Inc.|AMGN - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Amgen Corp|AMGN - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Amgen|AMGN - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan amgen.com|AMGN - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Amgen Inc.

- data dodolan lan asil:

AMGN - Pendapatan reged perusahaan|Prakiraan volume dodolan Amgen Corp|AMGN - Multiplikator P/S|Rasio rega marang prakiraan pendapatan Amgen Inc.

Analisis wiwitan perusahaan:Amgen Inc.

The effectiveness of the M&A strategy of Amgen Inc. (AMGN) determines the overall financial stability of the business. Earnings per share dynamics reflect the growth rate of net income relative to the previous quarter. This metric reveals hidden market imbalances and the actual resilience of the capital. It is critical for investors to evaluate the synergy from the acquisition of biotech startups through the lens of profitability. Analysis based on the quarterly change in EPS allows for the timely detection of a slowdown in operational efficiency.

Pesaing utama